Eight Mile Plains
Australia - Map
Phone: 61 7 3340 0200
Fax: 61 7 3340 0222
Alchemia Limited, a biotechnology company, engages in developing human therapeutic products based on its proprietary drug discovery and synthesis technologies in Australia and the United States. The company operates through Fondaparinux and HyACT segments. It provides generic Fondaparinux, an injectable anticoagulant drug for the prevention and treatment of deep vein thrombosis and pulmonary embolism. The company also offers HyACT, a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid as a drug delivery vehicle for a range of approved anti-cancer therapeutics. In addition, it is developing HA-Irinotecan that is in the Phase II clinical trials for the treatment of small cell lung cancer. The company has collaboration agreement with Merck Serono to develop HA-Irinotecan in combination with therapeutic antibody, Erbitux (cetuximab), for patients with metastatic colorectal cancer. Alchemia Limited was founded in 1995 and is headquartered in Brisbane, Australia.
|Dr. Tracey Jean Brown B.Sc., Ph.D.,
Chief Scientific Officer, VP of Oncology and Member of Clinical Advisory Board
|Ms. Melanie Jaye Leydin B.Bus (Acc/Law), CA,
Chief Financial Officer and Company Sec.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in AUD.|